AI SCIENCE
Google’s AI is in the lab
Alphabet’s AI drug discovery arm, Isomorphic Labs, is getting ready to launch its first human trials, an important step in using AI to rethink how medicines are developed.
Set up in 2021 from DeepMind’s AlphaFold protein modelling project, Isomorphic brings together AI and pharmaceutical research to design drugs more quickly and accurately.
Colin Murdoch, president of Isomorphic and a senior exec at Google DeepMind, told Fortune that trials for its AI-created treatments are nearly underway.
Here’s what you should know:
Human trials for AI-designed drugs are about to begin
Isomorphic Labs raised $600M and partnered with Eli Lilly and Novartis
The company says AI could speed up and improve drug discovery
The company’s growth has been fast.
This year, it secured $600 million in funding and struck research partnerships with pharmaceutical giants Eli Lilly and Novartis.
Alongside supporting its partners, Isomorphic is also developing its own early-stage drug candidates.
Murdoch said AI has the potential to cut down on both time and cost in drug development, and increase the chances of success.
AI curing diseases while I still Google my symptoms, lol.